• BCRT

In situ Tissue Engineering

Michael Sittinger

The team of Michael Sittinger has nearly 30 years of experience with pioneering work in the field of 'Tissue Engineering'. Their current work specifically adresses individual translational challenges and missing links for feasibility of regenerative therapies in different clinical research areas.

[Translate to englisch:]

Prof. Michael Sittinger

E-mail:
Michael.Sittinger[at]bih-charite.de
Address:
BIH Centrum für Regenerative Therapien
Augustenburger Platz 1
13353 Berlin

Research focus

The research strategy is focused on stimulation of natural endogenous healing which includes technologies in cell isolation, cell culture and cell quality control and controlled delivery of cells or tissue-forming bioactive factors into the patient. Appropriate handling of cells, factors and delivery materials is directed towards safety and quality requirements of the current regulatory framework to enable feasible and cost-efficient regenerative medical products.

The Tissue Engineering team contributes clinical and commercialization translation of regenerative therapies and products of different clinical research areas.

  • Topics include: Tissue Engineering, Cell-Based Therapies, resorbable biomaterials, 3D in-vitro disease models, bioprinting, bioreactors, cell production, local cell and factor release.
  • Team is currently involved in research and development of treatments for degenerative diseases of the heart muscle, articular cartilage, mandibular bone, neurodegenerative-disorder and spinal disc.

Selected publications

  • Selected publications

    CCL25-Supplemented Hyaluronic Acid Attenuates Cartilage Degeneration in a Guinea Pig Model of Knee Osteoarthritis. J Orthop Res. 2019. Präklinische In vivo Wirksamkeit einer neuen regenerativen Behandlung der Arthrose. Diese Technologie ist geschützt durch Patente der Charité.
    ​​​​​
    Toward in situ tissue engineering: chemokine-guided stem cell recruitment. Trends Biotechnol. 2014. Übersicht zur Technologie der Geweberegeneration durch Mobilisierung mesenchymaler Zellen.

    Endomyocardial biopsy derived adherent proliferating cells - a potential cell source for cardiac tissue engineering. J Cell Biochem. 2010. Entdeckung spezieller Herzzellen. Diese inzwischen als CardAP bezeichneten Zellen befinden sich derzeit in klinischer Entwicklung zur Behandlung chronischer Herzmuskelschwäche. Diese Technologie ist geschützt durch Patente der Charité.

    Regenerative medicine: Selecting the right biological scaffold for tissue engineering. Nat Rev Rheumatol. 2014. Kompakte angewandte Betrachtung zur Verwendung von Biomaterialien beim Tissue Engineering.

    Long-Term Clinical and MRI Results of Matrix-Assisted Autologous Chondrocyte Implantation for Articular Cartilage Defects of the Knee. Cartilage. 2019. 12-Jahre klinische Langzeitergebnisse zu einer früheren Knorpeltransplantatentwicklung des Teams.

Spin-offs

  • TransTissue Technologies GmbH
  • CellServe GmbH
  • BioRetis GmbH